Sun Kristie J, Jun Albert S, Bohm Kelley, Daroszewski Daniel, Jabbour Samir
Case Western Reserve University School of Medicine, 9501 Euclid Ave, Cleveland, OH, USA, 44106.
The Johns Hopkins Wilmer Eye Institute, 1800 Orleans St, Baltimore, MD, USA, 21287.
Am J Ophthalmol Case Rep. 2022 Jun 24;27:101618. doi: 10.1016/j.ajoc.2022.101618. eCollection 2022 Sep.
To describe the occurrence of corneal thinning in a patient following intrastromal injection of bevacizumab to treat lipid keratopathy.
A 36-year-old female presented with decreased vision in her right eye with central posterior corneal haze and underwent a treatment regimen including artificial tears, cyclosporine 0.05% drops, prednisolone 1% and oral Valacyclovir 1g with no improvement. Neovascularization was noted at 18 months follow up and treated with intrastromal bevacizumab injections at 24 months. The feeder vessel was attenuated at 3- and 6-months post-injection, but tomography indicated sustained thinning and flattening of the cornea at the injection site contributing to the development of irregular astigmatism.
Corneal thinning is an uncommon potential side effect of intrastromal bevacizumab injection that may affect postoperative visual acuity.
描述在基质内注射贝伐单抗治疗脂质角膜病变的患者中角膜变薄的发生情况。
一名36岁女性右眼视力下降，角膜后中央出现混浊，接受了包括人工泪液、0.05%环孢素滴眼液、1%泼尼松龙和口服1g伐昔洛韦的治疗方案，但病情无改善。随访18个月时发现新生血管形成，并在24个月时用基质内注射贝伐单抗进行治疗。注射后3个月和6个月时，供血血管变细，但断层扫描显示注射部位角膜持续变薄和扁平，导致不规则散光的发展。
角膜变薄是基质内注射贝伐单抗罕见的潜在副作用，可能影响术后视力。
